A Phase 1 Study of LY2606368 in Japanese Patients with Advanced Solid Tumors
- Conditions
- eoplasm
- Registration Number
- JPRN-jRCT2080222962
- Lead Sponsor
- Eli Lilly Japan K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Participant must be appropriate candidate for experimental therapy, as determined by investigator, after available standard therapies have failed
Participant must have diagnosis of cancer that is advanced or metastatic
Participant must have discontinued previous treatments for cancer and recovered from the acute effects of that therapy
If participant is of reproductive potential, must agree to use medically approved contraceptive precautions during the study and for three months following the last dose of study drug
If the participant is a female of childbearing potential, must have had a negative serum or urine pregnancy test within 7 days of the first dose of study drug and must not be breast feeding
Participant must not have symptomatic central nervous system malignancy or metastasis
Participant must not have current hematologic malignancy
Participant must not have an active symptomatic fungal, bacterial or viral infection, including human immunodeficiency virus (HIV) or Hepatitis A, B, or C
Participant must not have a serious cardiac condition
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method